동물용 의약품 시장 예측(-2031년) : 제품(의약품, 모노클로널 항체, 면역 조절제, 약용 사료첨가제), 투여 경로, 제형, 적응증, 동물 유형(반려동물, 가축), 유통 채널, 최종사용자별

The global veterinary pharmaceuticals market is projected to grow at a CAGR of 6.3% from 2026 to 2031, reflecting steady expansion across both companion and livestock segments.

Growth is supported by rising pet humanization, increasing prevalence of chronic and infectious diseases, and higher spending on advanced therapeutics. In livestock, productivity pressures and stricter food safety standards continue to drive pharmaceutical demand, sustaining consistent mid-single-digit market growth.

"By product type, the monoclonal antibodies segment is expected to witness the fastest growth rate during the forecast period."

The monoclonal antibodies segment is expected to grow fastest in the global veterinary pharmaceuticals market, supported by a growing preference for targeted and durable treatment options, especially in companion animals. The rising burden of chronic disorders, including atopic dermatitis, osteoarthritis, and immune-mediated conditions, is boosting demand. These therapies offer precise action, fewer adverse effects, and longer dosing intervals, improving compliance. Continued investment in biologics development and the expanding premium pet care market are further driving segment expansion.

"By indication, the dermatological diseases segment has accounted for the largest share in the Veterinary pharmaceuticals market in 2025."

The dermatological conditions segment is projected to hold the largest share of the global veterinary pharmaceuticals market in 2025, primarily due to the widespread occurrence of skin-related disorders in both companion and livestock animals. Common conditions such as atopic dermatitis, parasitic infections, fungal diseases, and bacterial skin infections require ongoing management and medication. Growing pet adoption, heightened focus on animal hygiene, and strong demand for anti-parasitic, antifungal, and anti-inflammatory treatments continue to reinforce the segment's dominant position.

"North America dominated the global veterinary pharmaceuticals market in 2025."

North America leads the veterinary pharmaceuticals market in 2025, supported by a mature animal healthcare ecosystem and strong purchasing power. The region records high spending on companion animal treatments and maintains a large commercial livestock base. Robust R&D investments, rapid approval pathways for innovative drugs, and the strong presence of established manufacturers further strengthen its position. Well-developed distribution networks and growing awareness of preventive animal care also contribute to its leading market position.

Breakdown of supply-side primary interviews:

• By Company Type: Tier 1 - 45%, Tier 2 - 20%, and Tier 3 - 35%
• By Designation: C-level - 35%, Director-level - 25%, and Others - 40%
• By Region: North America - 40%, Europe - 25%, APAC - 20%, Latin America - 10%, Middle East & Africa - 5%

Research Coverage

This report examines the veterinary pharmaceuticals market by product type, route of administration, formulation type, indications, animal type, distribution channel, end user, and region. It also examines factors (such as drivers, restraints, opportunities, and challenges) that affect market growth. It analyzes market opportunities and challenges and provides details on the competitive landscape for market leaders. Furthermore, the report analyzes micro-markets by their individual growth trends and forecasts market segment revenue across five main regions and their respective countries.

Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms gauge the market pulse, which, in turn, would help them gain a greater share. Firms purchasing the report could use one or a combination of the following five strategies.

This report provides insights into the following pointers:

• Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the veterinary pharmaceuticals market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the veterinary pharmaceuticals market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of catheterization procedures across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the veterinary pharmaceuticals market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the veterinary pharmaceuticals market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS AND EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS

2 EXECUTIVE SUMMARY

• 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
• 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS IN VETERINARY PHARMACEUTICALS MARKET
• 2.4 HIGH-GROWTH SEGMENTS
• 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN VETERINARY PHARMACEUTICALS MARKET
• 3.2 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE AND COUNTRY
• 3.3 VETERINARY PHARMACEUTICALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 3.4 VETERINARY PHARMACEUTICALS MARKET: DEVELOPING VS. DEVELOPED ECONOMIES, 2026-2031

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Rising companion animal ownership and pet humanization
    • 4.2.1.2 Growing prevalence of infectious and dermatological diseases in animals
    • 4.2.1.3 Increasing demand for animal-derived food products
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Growing concerns over antimicrobial resistance (AMR)
    • 4.2.2.2 Stringent regulatory approval processes for veterinary drugs
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Rising demand for parasiticides and dermatology products
    • 4.2.3.2 Growth potential in rural and low-income regions
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Monitoring drug residues in food-producing animals
    • 4.2.4.2 Balancing animal welfare, productivity, and compliance requirements
• 4.3 UNMET NEEDS AND WHITE SPACES
• 4.4 INTERCONNECTED MARKET AND CROSS-SECTOR OPPORTUNITIES
  • 4.4.1 INTERCONNECTED MARKETS
  • 4.4.2 CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 THREAT OF SUBSTITUTES
  • 5.1.3 BARGAINING POWER OF SUPPLIERS
  • 5.1.4 BARGAINING POWER OF BUYERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMICS INDICATORS
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS AND FORECAST
  • 5.2.3 TRENDS IN GLOBAL ANIMAL HEALTHCARE INDUSTRY
  • 5.2.4 TRENDS IN GLOBAL VETERINARY PHARMACEUTICALS INDUSTRY
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 SUPPLY CHAIN ANALYSIS
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 PRICING ANALYSIS
  • 5.6.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYERS, 2023-2025
  • 5.6.2 AVERAGE SELLING PRICE TREND OF FORMULATION TYPES, BY KEY PLAYERS, 2023-2025
  • 5.6.3 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2023-2025
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT DATA FOR HS CODE 30, 2021-2024
    • 5.7.1.1 Import scenario (HS code 30)
  • 5.7.2 EXPORT DATA FOR HS CODE 30, 2021-2024
  • 5.7.3 EXPORT SCENARIO (HS CODE 30)
• 5.8 KEY CONFERENCES AND EVENTS IN 2026-2027
• 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.10 INVESTMENT AND FUNDING SCENARIO
• 5.11 CASE STUDY ANALYSIS
  • 5.11.1 ZOETIS INC.
  • 5.11.2 BOEHRINGER INGELHEIM ANIMAL HEALTH
  • 5.11.3 MERCK ANIMAL HEALTH
  • 5.11.4 ELANCO ANIMAL HEALTH
  • 5.11.5 CEVA SANTE ANIMALE
• 5.12 IMPACT OF 2025 US TARIFF - VETERINARY PHARMACEUTICALS MARKET
  • 5.12.1 INTRODUCTION
  • 5.12.2 KEY TARIFF RATES
  • 5.12.3 PRICE IMPACT ANALYSIS
  • 5.12.4 IMPACT ON REGIONS
    • 5.12.4.1 North America
    • 5.12.4.2 Europe
    • 5.12.4.3 Asia Pacific
  • 5.12.5 IMPACT ON END-USE INDUSTRIES
    • 5.12.5.1 Veterinary hospitals & clinics
    • 5.12.5.2 Home care settings
    • 5.12.5.3 Livestock farms
    • 5.12.5.4 Rescue centers & NGOs
    • 5.12.5.5 Other end users

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 TECHNOLOGY ANALYSIS
  • 6.1.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1.1 Controlled release formulation
    • 6.1.1.2 Biologics and monoclonal antibodies
  • 6.1.2 COMPLEMENTARY TECHNOLOGIES
    • 6.1.2.1 Digital health and telemedicine platforms
    • 6.1.2.2 Veterinary biomarker analysis
  • 6.1.3 ADJACENT TECHNOLOGIES
    • 6.1.3.1 Wearable animal health monitoring devices
    • 6.1.3.2 Stem cell therapy and regenerative medicine
• 6.2 TECHNOLOGY/PRODUCT ROADMAP
• 6.3 PATENT ANALYSIS
  • 6.3.1 PUBLICATION TRENDS FOR VETERINARY PHARMACEUTICALS
  • 6.3.2 INSIGHTS ON PATENT PUBLICATION TRENDS, TOP APPLICANTS AND JURISDICTION FOR VETERINARY PHARMACEUTICALS MARKET, JANUARY 2015-DECEMBER 2025
  • 6.3.3 LIST OF MAJOR PATENTS, 2023-2025
• 6.4 FUTURE APPLICATIONS
  • 6.4.1 PRECISION LIVESTOCK HEALTH MANAGEMENT
  • 6.4.2 ONCOLOGY AND CHRONIC DISEASE MANAGEMENT
  • 6.4.3 REPRODUCTIVE AND FERTILITY ENHANCEMENT IN LIVESTOCK
  • 6.4.4 INTEGRATED DISEASE SURVEILLANCE AND OUTBREAK CONTROL
• 6.5 IMPACT OF GEN AI ON VETERINARY PHARMACEUTICALS MARKET

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

• 7.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 7.1.1 REGULATORY FRAMEWORK
    • 7.1.1.1 North America
    • 7.1.1.2 Europe
  • 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.3 INDUSTRY STANDARDS
    • 7.1.3.1 VICH Guidelines (International Co-operation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products)
    • 7.1.3.2 Good Manufacturing Practice (GMP) Standards - PIC/S Guide (PE 009 series)
    • 7.1.3.3 Codex Alimentarius Standards for Veterinary Drug Residues (CXM 2 - Maximum Residue Limits)
• 7.2 SUSTAINABILITY INITIATIVES
  • 7.2.1 ECO-FRIENDLY AND RECYCLABLE MATERIALS IN VETERINARY PHARMACEUTICALS MARKET
    • 7.2.1.1 Virbac - Eco-pack to reduce single-use plastic in veterinary products
    • 7.2.1.2 Boehringer Ingelheim Animal Health - Renewable energy-powered manufacturing
    • 7.2.1.3 Boehringer Ingelheim - Recyclable veterinary delivery device (Aservo, EquiHaler)
• 7.3 CERTIFICATIONS, LABELING, ECO-STANDARDS

8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 BUYING CRITERIA
• 8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
• 8.4 UNMET NEEDS IN VARIOUS END-USE SETTINGS
• 8.5 MARKET PROFITABILITY
  • 8.5.1 PRODUCT INNOVATION AND DIFFERENTIATION
  • 8.5.2 EXPANSION OF COMPANION ANIMAL HEALTHCARE SPENDING
  • 8.5.3 OPERATIONAL SCALE AND DISTRIBUTION EFFICIENCY

9 VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE

• 9.1 INTRODUCTION
  • 9.1.1 VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024-2031 (THOUSAND UNITS)
• 9.2 DRUGS
  • 9.2.1 ANTI-BACTERIAL DRUGS
    • 9.2.1.1 Routine use in livestock and companion animals underpins strong market share and steady growth
  • 9.2.2 ANTI-FUNGAL DRUGS
    • 9.2.2.1 Limited approvals and off-label systemic use result in smaller but clinically essential segment
  • 9.2.3 ANTI-VIRAL DRUGS
    • 9.2.3.1 Low current penetration but rising research interest driven by outbreak response and targeted therapies
  • 9.2.4 ANTI-INFLAMMATORY DRUGS
    • 9.2.4.1 Rising surgical volumes and chronic pain management drive stable double-digit market share
  • 9.2.5 ANTI-PARASITIC DRUGS
    • 9.2.5.1 High parasitic burden and preventive care practices sustain market share and strong growth trajectory
  • 9.2.6 ANTI-CANCER DRUGS
    • 9.2.6.1 Increasing pet oncology awareness and advanced therapeutics to fuel growth from small base
  • 9.2.7 CARDIOVASCULAR AND RENAL DRUGS
    • 9.2.7.1 Rising diagnosis of chronic heart and kidney disorders supports steady mid-single-digit market share
  • 9.2.8 GASTROINTESTINAL DRUGS
    • 9.2.8.1 High incidence of digestive disorders and dietary transitions drive sustained demand
  • 9.2.9 OTHER DRUGS
• 9.3 MONOCLONAL ANTIBODIES
  • 9.3.1 TARGETED BIOLOGICS AND RISING COMPANION ANIMAL THERAPEUTICS TO DRIVE DEMAND
• 9.4 IMMUNOMODULATORS
  • 9.4.1 INCREASING FOCUS ON IMMUNE-MEDIATED DISEASES AND PREVENTIVE HEALTH TO SUPPORT GRADUAL EXPANSION FROM SMALLER BASE
• 9.5 MEDICATED FEED ADDITIVES
  • 9.5.1 AMINO ACIDS
    • 9.5.1.1 Protein optimization and feed cost efficiency to drive demand
  • 9.5.2 ENZYMES
    • 9.5.2.1 Improved nutrient digestibility and cost optimization to support steady adoption
  • 9.5.3 VITAMINS AND MINERALS
    • 9.5.3.1 Essential micronutrient supplementation ensures largest market share
  • 9.5.4 OTHER MEDICATED FEED ADDITIVES

10 VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION

• 10.1 INTRODUCTION
• 10.2 ORAL
  • 10.2.1 EASE OF DOSING AND HIGH COMPLIANCE IN COMPANION AND LIVESTOCK ANIMALS
• 10.3 PARENTERAL
  • 10.3.1 RAPID THERAPEUTIC ACTION AND HIGHER BIOAVAILABILITY IN CRITICAL CARE AND PRODUCTION SETTINGS
• 10.4 TOPICAL
  • 10.4.1 RISING DERMATOLOGY CASES AND DEMAND FOR LOCALIZED, NON-INVASIVE TREATMENTS
• 10.5 OTHER ROUTES OF ADMINISTRATION

11 VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE

• 11.1 INTRODUCTION
• 11.2 SOLID
  • 11.2.1 DOSING STABILITY, COST EFFICIENCY, AND EASE OF LARGE-SCALE ADMINISTRATION IN LIVESTOCK AND COMPANION ANIMALS
• 11.3 LIQUID
  • 11.3.1 RAPID ABSORPTION, FLEXIBLE DOSING, AND SUITABILITY FOR INJECTABLES AND ORAL SUSPENSIONS
• 11.4 SEMI-SOLID
  • 11.4.1 RISING DERMATOLOGY CASES AND INCREASING COMPANION ANIMAL CARE EXPENDITURE
• 11.5 AEROSOL/SPRAY
  • 11.5.1 CONVENIENCE, TARGETED DELIVERY, AND REDUCED CROSS-CONTAMINATION RISK
• 11.6 PREMIX FORMULATIONS
  • 11.6.1 DEMAND FOR MEDICATED FEED AND PREVENTIVE HERD-LEVEL DISEASE MANAGEMENT TO DRIVE MARKET

12 VETERINARY PHARMACEUTICALS MARKET, BY INDICATION

• 12.1 INTRODUCTION
• 12.2 INFECTIOUS DISEASES
  • 12.2.1 ZOONOTIC RISK AND LIVESTOCK DISEASE CONTROL PROGRAMS TO DRIVE MARKET
• 12.3 DERMATOLOGICAL DISEASES
  • 12.3.1 RISING CHRONIC SKIN CONDITIONS AND PREMIUM COMPANION ANIMAL SPENDING TO DRIVE MARKET
• 12.4 PAIN MANAGEMENT
  • 12.4.1 RISING SURGICAL PROCEDURES AND AGING PET POPULATION TO DRIVE MARKET
• 12.5 CARDIOVASCULAR AND RENAL DISEASES
  • 12.5.1 INCREASED DIAGNOSIS IN AGING COMPANION ANIMALS TO DRIVE MARKET
• 12.6 GASTROINTESTINAL DISEASES
  • 12.6.1 HIGH PREVALENCE OF ENTERIC INFECTIONS AND DIETARY DISORDERS TO DRIVE MARKET
• 12.7 OTHER INDICATIONS

13 VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE

• 13.1 INTRODUCTION
• 13.2 COMPANION ANIMALS
  • 13.2.1 DOGS
    • 13.2.1.1 Increasing population and adoption of dogs to drive market
  • 13.2.2 CATS
    • 13.2.2.1 Emerging trends in feline pharmaceuticals to boost market
  • 13.2.3 HORSES
    • 13.2.3.1 Higher risk of traumatic injuries in horses to drive demand for veterinary pharmaceutical products
  • 13.2.4 OTHER COMPANION ANIMALS
• 13.3 LIVESTOCK ANIMALS
  • 13.3.1 CATTLE
    • 13.3.1.1 Economic importance of dairy and beef cattle to drive growth
  • 13.3.2 SWINE
    • 13.3.2.1 Growing surgical volume for acute conditions in swine to drive market
  • 13.3.3 POULTRY
    • 13.3.3.1 Growing focus on infection prevention and flock health management to drive market
  • 13.3.4 OTHER LIVESTOCK ANIMALS

14 VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL

• 14.1 INTRODUCTION
• 14.2 VETERINARY HOSPITAL PHARMACIES
  • 14.2.1 HIGH IMPORTANCE AND BETTER OPPORTUNITIES IN ON-FARM VETERINARY PHARMACEUTICALS TO DRIVE MARKET
• 14.3 RETAIL PHARMACIES
  • 14.3.1 RETAIL PHARMACIES TO AID ACCESSIBILITY AND MARKET REACH IN VETERINARY PHARMACEUTICALS
• 14.4 ONLINE PHARMACIES
  • 14.4.1 CONVENIENCE AND ACCESSIBILITY TO AUGMENT MARKET GROWTH
• 14.5 DIRECT SALES
  • 14.5.1 DIRECT SALES TO STRENGTHEN MANUFACTURER-TO-CUSTOMER CONNECTIONS

15 VETERINARY PHARMACEUTICALS MARKET, BY END USER

• 15.1 INTRODUCTION
• 15.2 VETERINARY HOSPITALS & CLINICS
  • 15.2.1 FIRST POINT OF CONTACT FOR ANIMAL OWNERS AND LIVESTOCK CAREGIVERS
• 15.3 LIVESTOCK FARMS
  • 15.3.1 GROWING IMPORTANCE AND OPPORTUNITIES IN ON-FARM ANIMAL CARE
• 15.4 HOME CARE SETTINGS
  • 15.4.1 RISING PET EXPENDITURE TO PROPEL SEGMENT GROWTH
• 15.5 OTHER END USERS

16 VETERINARY PHARMACEUTICALS MARKET, BY REGION

• 16.1 INTRODUCTION
• 16.2 NORTH AMERICA
  • 16.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 16.2.2 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024-2031 (THOUSAND UNITS)
  • 16.2.3 US
    • 16.2.3.1 Surge in animal healthcare expenditure to boost market
  • 16.2.4 CANADA
    • 16.2.4.1 Growing pet population and advanced veterinary services to drive market
• 16.3 EUROPE
  • 16.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 16.3.2 EUROPE: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024-2031 (THOUSAND UNITS)
  • 16.3.3 GERMANY
    • 16.3.3.1 Increased focus on animal welfare to drive demand for veterinary pharmaceutical products
  • 16.3.4 UK
    • 16.3.4.1 Increasing pet ownership to propel market
  • 16.3.5 FRANCE
    • 16.3.5.1 High standards of veterinary care to provide attractive growth opportunities for market players
  • 16.3.6 ITALY
    • 16.3.6.1 Growing pet owner awareness and increasing livestock population to drive market
  • 16.3.7 SPAIN
    • 16.3.7.1 Increasing awareness of animal health to drive market
  • 16.3.8 REST OF EUROPE
• 16.4 ASIA PACIFIC
  • 16.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 16.4.2 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024-2031 (THOUSAND UNITS)
  • 16.4.3 JAPAN
    • 16.4.3.1 Surge in pet care expenditure and growing adoption of companion animals to drive market
  • 16.4.4 CHINA
    • 16.4.4.1 Increasing animal healthcare expenditure and advancements in veterinary medicines to drive market
  • 16.4.5 INDIA
    • 16.4.5.1 Increasing livestock population to propel market growth
  • 16.4.6 AUSTRALIA
    • 16.4.6.1 Growing companion animal ownership and rise in animal health awareness to support market growth
  • 16.4.7 SOUTH KOREA
    • 16.4.7.1 Growing pet ownership and advancements in veterinary medicine to favor market growth
  • 16.4.8 PHILIPPINES
    • 16.4.8.1 Tourism-linked pet culture and veterinary advancements to fuel market
  • 16.4.9 REST OF ASIA PACIFIC
• 16.5 LATIN AMERICA
  • 16.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 16.5.2 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024-2031 (THOUSAND UNITS)
  • 16.5.3 BRAZIL
    • 16.5.3.1 Growing pet population and rising disposable incomes to drive market
  • 16.5.4 MEXICO
    • 16.5.4.1 Robust livestock base and growing companion animal care to drive market
  • 16.5.5 REST OF LATIN AMERICA
• 16.6 MIDDLE EAST & AFRICA
  • 16.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 16.6.2 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024-2031 (THOUSAND UNITS)
• 16.7 GCC COUNTRIES
  • 16.7.1 KINGDOM OF SAUDI ARABIA (KSA)
    • 16.7.1.1 Vision 2030 investments to drive market
  • 16.7.2 UNITED ARAB EMIRATES (UAE)
    • 16.7.2.1 Increasing adoption of advanced diagnostic technologies to contribute to market growth
  • 16.7.3 REST OF GCC COUNTRIES
  • 16.7.4 REST OF MIDDLE EAST & AFRICA

17 COMPETITIVE LANDSCAPE

• 17.1 INTRODUCTION
  • 17.1.1 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2023-2026
• 17.2 REVENUE ANALYSIS, 2023-2025
• 17.3 MARKET SHARE ANALYSIS, 2025
  • 17.3.1 US: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025
  • 17.3.2 EUROPE: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025
• 17.4 PRODUCT/BRAND COMPARISON
• 17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 17.5.1 STARS
  • 17.5.2 EMERGING LEADERS
  • 17.5.3 PERVASIVE PLAYERS
  • 17.5.4 PARTICIPANTS
  • 17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 17.5.5.1 Company footprint
    • 17.5.5.2 Region footprint
    • 17.5.5.3 Product type footprint
    • 17.5.5.4 Route of administration footprint
    • 17.5.5.5 Indication footprint
    • 17.5.5.6 End user footprint
• 17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 17.6.1 PROGRESSIVE COMPANIES
  • 17.6.2 RESPONSIVE COMPANIES
  • 17.6.3 DYNAMIC COMPANIES
  • 17.6.4 STARTING BLOCKS
  • 17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 17.6.5.1 Detailed list of key startups/SMEs
    • 17.6.5.2 Competitive benchmarking of key startups/SMEs
• 17.7 COMPANY VALUATION AND FINANCIAL METRICS
• 17.8 COMPETITIVE SCENARIO
  • 17.8.1 PRODUCT LAUNCHES & APPROVALS
  • 17.8.2 DEALS
  • 17.8.3 EXPANSIONS
  • 17.8.4 OTHER DEVELOPMENTS

18 COMPANY PROFILES

• 18.1 KEY PLAYERS
  • 18.1.1 ZOETIS INC.
    • 18.1.1.1 Business overview
    • 18.1.1.2 Products offered
    • 18.1.1.3 Recent developments
      • 18.1.1.3.1 Product launches & approvals
      • 18.1.1.3.2 Expansions
      • 18.1.1.3.3 Other developments
    • 18.1.1.4 MnM view
      • 18.1.1.4.1 Right to win
      • 18.1.1.4.2 Strategic choices
      • 18.1.1.4.3 Weaknesses and competitive threats
  • 18.1.2 MERCK & CO., INC
    • 18.1.2.1 Business overview
    • 18.1.2.2 Products offered
    • 18.1.2.3 Recent developments
      • 18.1.2.3.1 Product launches & approvals
      • 18.1.2.3.2 Deals
      • 18.1.2.3.3 Expansions
    • 18.1.2.4 MnM view
      • 18.1.2.4.1 Right to win
      • 18.1.2.4.2 Strategic choices
      • 18.1.2.4.3 Weaknesses and competitive threats
  • 18.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 18.1.3.1 Business overview
    • 18.1.3.2 Products offered
    • 18.1.3.3 Recent developments
      • 18.1.3.3.1 Product launches & approvals
      • 18.1.3.3.2 Deals
      • 18.1.3.3.3 Expansions
    • 18.1.3.4 MnM view
      • 18.1.3.4.1 Right to win
      • 18.1.3.4.2 Strategic choices
      • 18.1.3.4.3 Weaknesses and competitive threats
  • 18.1.4 ELANCO ANIMAL HEALTH INCORPORATED
    • 18.1.4.1 Business overview
    • 18.1.4.2 Products offered
    • 18.1.4.3 Recent developments
      • 18.1.4.3.1 Product launches & approvals
      • 18.1.4.3.2 Expansions
      • 18.1.4.3.3 Other developments
    • 18.1.4.4 MnM view
      • 18.1.4.4.1 Right to win
      • 18.1.4.4.2 Strategic choices
      • 18.1.4.4.3 Weaknesses and competitive threats
  • 18.1.5 VIRBAC
    • 18.1.5.1 Business overview
    • 18.1.5.2 Products offered
    • 18.1.5.3 Recent developments
      • 18.1.5.3.1 Product launches & approvals
      • 18.1.5.3.2 Deal
      • 18.1.5.3.3 Expansions
    • 18.1.5.4 MnM view
      • 18.1.5.4.1 Right to win
      • 18.1.5.4.2 Strategic choices
      • 18.1.5.4.3 Weaknesses and competitive threats
  • 18.1.6 CEVA
    • 18.1.6.1 Business overview
    • 18.1.6.2 Products offered
    • 18.1.6.3 Recent developments
      • 18.1.6.3.1 Deals
      • 18.1.6.3.2 Expansions
  • 18.1.7 VETOQUINOL
    • 18.1.7.1 Business overview
    • 18.1.7.2 Products offered
    • 18.1.7.3 Recent developments
      • 18.1.7.3.1 Product launches & approvals
      • 18.1.7.3.2 Deals
  • 18.1.8 DECHRA PHARMACEUTICALS PLC
    • 18.1.8.1 Business overview
    • 18.1.8.2 Products offered
    • 18.1.8.3 Recent developments
      • 18.1.8.3.1 Product launches & approvals
      • 18.1.8.3.2 Deals
      • 18.1.8.3.3 Other developments
  • 18.1.9 NORBROOK
    • 18.1.9.1 Business overview
    • 18.1.9.2 Products offered
    • 18.1.9.3 Recent developments
      • 18.1.9.3.1 Product launches & approvals
      • 18.1.9.3.2 Deals
      • 18.1.9.3.3 Expansions
      • 18.1.9.3.4 Other developments
  • 18.1.10 BIMEDA CORPORATE
    • 18.1.10.1 Business overview
    • 18.1.10.2 Products offered
    • 18.1.10.3 Recent developments
      • 18.1.10.3.1 Product launches & approvals
      • 18.1.10.3.2 Deals
      • 18.1.10.3.3 Expansions
  • 18.1.11 HESTER BIOSCIENCES LIMITED
    • 18.1.11.1 Business overview
    • 18.1.11.2 Products offered
  • 18.1.12 INDIAN IMMUNOLOGICALS LTD.
    • 18.1.12.1 Business overview
    • 18.1.12.2 Products offered
  • 18.1.13 ANIMALCARE GROUP PLC
    • 18.1.13.1 Business overview
    • 18.1.13.2 Products offered
    • 18.1.13.3 Recent developments
      • 18.1.13.3.1 Deals
      • 18.1.13.3.2 Product launches & approvals
  • 18.1.14 KYORITSU SEIYAKU CORPORATION
    • 18.1.14.1 Business overview
    • 18.1.14.2 Products offered
    • 18.1.14.3 Recent developments
      • 18.1.14.3.1 Product launches & approvals
      • 18.1.14.3.2 Deals
  • 18.1.15 CALIER
    • 18.1.15.1 Business overview
    • 18.1.15.2 Products offered
    • 18.1.15.3 Recent developments
      • 18.1.15.3.1 Product launches & approvals
• 18.2 OTHER PLAYERS
  • 18.2.1 DOPHARMA
  • 18.2.2 PHARMGATE ANIMAL HEALTH
  • 18.2.3 BIOVETA, A.S.
  • 18.2.4 NEXTMUNE
  • 18.2.5 TRIVIUMVET
  • 18.2.6 DOMES PHARMA
  • 18.2.7 UNIVET LIMITED
  • 18.2.8 CENAVISA, S.L.
  • 18.2.9 FATRO S.P.A.
  • 18.2.10 CHANELLE PHARMA

19 RESEARCH METHODOLOGY

• 19.1 RESEARCH DATA
  • 19.1.1 SECONDARY DATA
    • 19.1.1.1 Key data from secondary sources
  • 19.1.2 PRIMARY DATA
    • 19.1.2.1 Key data from primary sources
    • 19.1.2.2 Key industry insights
    • 19.1.2.3 Key industry insights
• 19.2 MARKET SIZE ESTIMATION
• 19.3 GROWTH FORECAST
  • 19.3.1 KEY INDUSTRY INSIGHTS
• 19.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 19.5 RESEARCH ASSUMPTIONS
• 19.6 RESEARCH LIMITATIONS
• 19.7 RISK ASSESSMENT

20 APPENDIX

• 20.1 DISCUSSION GUIDE
• 20.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 20.3 CUSTOMIZATION OPTIONS
  • 20.3.1 PRODUCT ANALYSIS
  • 20.3.2 US END USER ANALYSIS
  • 20.3.3 GEOGRAPHIC ANALYSIS
  • 20.3.4 COMPANY INFORMATION
  • 20.3.5 REGIONAL/COUNTRY LEVEL MARKET SHARE ANALYSIS
  • 20.3.6 COUNTRY LEVEL VOLUME ANALYSIS BY PRODUCT TYPE
  • 20.3.7 BY PRODUCT TYPE MARKET SHARE ANALYSIS (TOP 5 PLAYERS)
  • 20.3.8 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST
• 20.4 RELATED REPORTS
• 20.5 AUTHOR DETAILS